Ginkgo Bioworks Stock

ginkgobioworks.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $785.53MM

Ginkgo Bioworks is the developer of a cell programming platform enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Register for Details

For more details on financing and valuation for Ginkgo Bioworks, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ginkgo Bioworks.

Register Today

Team

Management Team

Barry Canton
Co-Founder
Peter Boynton
Chief Commercial Officer
Austin Che
Co-Founder
Ena Cratsenburg
Chief Business Officer
Jason Kelly
Co-Founder, Chief Executive Officer & Board Member
Reshma Shetty
Co-Founder, President & Board Member
Tom Knight
Co-Founder

Board Members

Marjin Dekkers
Christian Henry

Other companies like Ginkgo Bioworks in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Ginkgo Bioworks to Acquire Swiss Bioengineering Firm FGen
FGen, a spinout of ETH Zurich, is a contract research organization specializing in strain development and optimization.
Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm
Project Beacon COVID-19 was started by F-Prime Capital, GV, and the Broad Institute to help implement COVID-19 testing in Massachusetts and its environs.
FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Today’s Important Deadline in Securities Class Action Commenced by the Firm – DNA, SRNG
NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo...
Updated on: Sep 22, 2023